A recent conference call by the leaders of Seattle Genetics brought some good news to the table. Total revenues for the second quarter of 2016 were up to $95.4 million, which was a marked improvement from last year, over 20%. The overall tone of the press release was very positive. The CEO of Seattle Genetics, Clay Siegall, Ph.D, observed, “I’m pleased by the progress we’ve made over the past several months.”
Clay Siegall‘s overall vision for Seattle Genetics is a company that develops antibodies that fight cancer. The success of their product indicates that the public and medical community has taken notice. Government statistics indicate cancer diagnosis rates are at 454.8 per 100,000 people, or roughly 1 in 200 people a year in the United States alone. This is unacceptably high, and explains the strong demand for Seattle Genetics antibody cancer products. Seattle Genetics specializes in treating lymphoma cancers, which occur from toxic build up in the human body’s lymph system.
Siegall says it this way, “Our goal is to redefine the way frontline HL and mature T-cell lymphoma patients are treated.” As a highly educated professional with degrees in Zoology and Genetics, Siegall feels qualified to tackle the challenge of beating cancer.
Seattle Genetics is headquartered in Bothell, Washington. It was founded in 1998 with the express goal of helping people who are living with cancer. Seattle Genetics has licensing agreements with drug industry megalith Pfizer, which has helped it garner helpful additional revenue.